B7-H3 Emerges as Prime Target for Prostate Cancer Across All Stages

A 2026 study published in Clinical Cancer Research has pinpointed B7-H3 as a standout therapeutic target for prostate cancer, offering hope against the disease’s toughest forms. The work analyzed tissue from prostate cancer patients across the full spectrum, from hormone-sensitive and castration-resistant to neuroendocrine and “double-negative” subtypes, revealing B7-H3’s consistent, broad expression. This uniformity stands out because advanced prostate cancers often dodge treatments through fleeting or androgen receptor (AR)-dependent surface proteins, but B7-H3 shows low variability between patients and within tumors, making it a reliable bullseye.

The team’s deep dive relied on JHU-PANORAMA, a massive single-cell transcriptomics atlas encompassing nearly 1 million cells from 213 patients, integrated with patient-derived xenograft (PDX) models. Proteomic checks on real patient samples and experiments in cell lines confirmed B7-H3’s presence at the protein level, while mechanistic studies showed it’s negatively regulated by AR signaling, meaning androgen deprivation therapy (ADT), a cornerstone of treatment, actually boosts its accessibility. Combining B7-H3 inhibition with ADT delivered synergistic tumor suppression, a combo with real potential to smash through resistance barriers that plague current options.

Beyond solo targeting, the study rolls out a smart framework for bispecific antibodies, scoring B7-H3 highly when paired with TROP-2, NECTIN1, KLK2, or NECTIN4 to widen the net against resistant cells. Now, JHU-PANORAMA lives on as a free interactive RShiny webapp, letting researchers worldwide explore prostate cancer’s cellular landscape in real time. This builds on years of buzz around B7-H3 (aka CD276), an immune checkpoint overexpressed in lethal castration-resistant prostate cancers (CRPC), as seen in prior trials with antibody-drug conjugates like DS-7300a.

For patients and oncologists, B7-H3 emerges as a “broad-spectrum” contender, ripe for therapies like CAR-T cells, bispecifics, or ADCs that could pair seamlessly with standard ADT. Its low heterogeneity sidesteps the pitfalls of patchy targets, positioning it to tackle the prostate cancer continuum head-on.

Source.